Great Point Partners LLC Unicycive Therapeutics, Inc. Transaction History
Great Point Partners LLC
- $162 Million
- Q1 2025
A detailed history of Great Point Partners LLC transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Great Point Partners LLC holds 10,980,000 shares of UNCY stock, worth $47.3 Million. This represents 3.87% of its overall portfolio holdings.
Number of Shares
10,980,000
Previous 10,980,000
-0.0%
Holding current value
$47.3 Million
Previous $8.67 Million
27.85%
% of portfolio
3.87%
Previous 5.72%
Shares
2 transactions
Others Institutions Holding UNCY
# of Institutions
20Shares Held
53.7MCall Options Held
0Put Options Held
0-
Octagon Capital Advisors LP New York, NY10MShares$43.1 Million1.9% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT9.39MShares$40.5 Million0.24% of portfolio
-
Silverarc Capital Management, LLC2.41MShares$10.4 Million0.33% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA2.35MShares$10.1 Million2.54% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL1.75MShares$7.54 Million0.0% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $64.9M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...